Indicated for use in hemodialysis patients for the treatment of stenoses in the venous outflow of an AV fistula and at the venous anastomosis of ePTFE or other synthetic AV grafts
–
BD Interventional
Fluency Plus Endovascular Stent Graft
Nitinol/ePTFE
8, 9, 10
0.035
6, 7, 8, 9, 10, 12, 13.5
40, 60, 80, 100, 120
80, 117
Indicated for use in the treatment of in-stent restenosis in the venous outflow of hemodialysis patients dialyzing by either an AVF or AV graft and for the treatment of stenosis in the venous outflow of hemodialysis patients dialyzing by an AV graft
5–8 mm indicated for symptomatic PAD lesions in the SFA up to 270 mm in length reference vessel diameters ranging from 4.0 to 7.5 mm; 5–7 mm indicated for symptomatic in-stent restenosis lesions in the SFA up to 270 mm in length with reference vessel diameters ranging from 4.0 to 6.5 mm; 5–13 mm indicated for symptomatic PAD lesions in the iliac artery up to 80 mm in length with reference vessel diameters ranging from 4.0 to 12 mm; also indicated for stenosis or thrombotic occlusion at venous anastomosis of synthetic AV access grafts
–
Gore & Associates
Gore Viabahn Endoprosthesis With Heparin Bioactive Surface
Nitinol/ePTFE, gold
6–10
0.018/0.014 (5–8 mm), 0.035 (5–13 mm)
5, 6, 7, 8, 9, 10, 11, 13
25, 50, 75, 100, 150, 250
75 (0.035-inch system only), 120
5–8 mm indicated for symptomatic PAD lesions in the SFA up to 270 mm in length reference vessel diameters ranging from 4.0 to 7.5 mm; 5–7 mm indicated for symptomatic in-stent restenosis lesions in the SFA up to 270 mm in length with reference vessel diameters ranging from 4.0 to 6.5 mm; 5–13 mm indicated for symptomatic PAD lesions in the iliac artery up to 80 mm in length with reference vessel diameters ranging from 4.0 to 12 mm; also indicated for stenosis or thrombotic occlusion at venous anastomosis of synthetic AV access grafts
–
Gore & Associates
Gore Viabil Biliary Endoprosthesis
Nitinol/ePTFE
10 (percutaneous)
0.035
8, 10
40, 60, 80, 100
40 (percutaneous)
Malignant biliary strictures*
*Contraindicated for all cardiovascular applications
Indicated for use in de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, ascites, and/or hepatic hydrothorax
Indicated for use in hemodialysis patients for the treatment of stenosis or occlusion within the dialysis access outflow circuit, including stenosis or occlusion; in the peripheral veins of individuals with an arteriovenous (AV) fistula; at the venous anastomosis of a synthetic AV graft
Prevents transmural cellular migration and tissue accumulation
Advertisement
Advertisement
We value keeping the Device Guide up to date.
If you want to add or update your company’s device listings, please let us know!